Management assessment of superficial venous thrombophlebitis in lower limb
Abstract
Background: Optimal doses and duration of anticoagulants or non‐steroidal anti‐inflammatory drugs (NSAIDs) for the treatment of superficial vein thrombosis (SVT) are still uncertain.
Objectives: To compare the efficacy and safety of therapuetic dose of rivaroxaban, prophylactic dose of rivaroxaban and oral non-steroidal anti-inflammatory drugs (Etorecoxib) for acute lower limb SVT.
Patients and methods: Inpatients and Outpatients with at least a 5-cm-long acute SVT of long or short saphenous veins or their collaterals were randomized to receive rivaroxaban either 10 mg once daily for a mounth (group A) or 20 mg once daily for a mounth (group B) or 90 mg etorecoxib once daily for a mounth (group C), in a double-blind fashion. The main outcome measure was to compare the rate of recurrence or extension of SVT (symptomatic and asymptomatic), DVT (symptomatic and asymptomatic), PE (symptomatic) and reduction in pain during a 3-month follow-up period. The main safety measure was death or major hemorrhage.
Results: Among 76 patients, the main complications occurred in 3/24 (12.5%), 4/27 (14.8%) and 4/25 (16%) subjects in groups (group A), (group B) and (group C), respectively. (group A) vs. (group B): P>0.05; (group A) or (group B) vs. (group C): P<0.05. During the 3-month follow-up period, the event rate was similar in all groups. No death or major hemorrhage occurred during the study.
Conclusions: A therapuetic dose or prophylactic dose of rivaroxaban is superior to oral non-steroidal anti-inflammatory drugs (Etorecoxib) for acute lower limb SVT during a mounth treatment period with similar results for a 3-month follow-up period.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.